Enthera develops first-in-class biologics targeting the IGFBP3/TMEM219 pathway to preserve and restore organ cell function in patients with severe autoimmune disorders. The company focuses on creating disease-modifying treatments for conditions such as Type 1 Diabetes and Inflammatory Bowel Disease, addressing the lack of effective therapies in this area.
Funding
$8.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
RVFounders
Product
Problem
Current treatments for severe autoimmune disorders often fail to restore organ cell function, leaving a significant unmet need for disease-modifying therapies. Conditions like Type 1 Diabetes and Inflammatory Bowel Disease lack effective treatments that address the underlying causes of cellular damage.
Solution
Enthera is developing first-in-class biologics that target the IGFBP3/TMEM219 pathway to preserve and restore organ cell function in patients with severe autoimmune disorders. Their therapeutic approach focuses on creating disease-modifying treatments for conditions such as Type 1 Diabetes and Inflammatory Bowel Disease. By targeting the IGFBP3/TMEM219 axis, a pathway involved in cell apoptosis in the gut, pancreas, and other organs, Enthera aims to transform the treatment paradigm for intractable autoimmune diseases. Their discovery engine delivers libraries of monoclonal antibodies (mAbs) and fusion proteins that target this pathway.
Target Audience
The primary target audience includes patients with severe autoimmune disorders, such as Type 1 Diabetes and Inflammatory Bowel Disease, and the healthcare providers who treat them.
Features
- First-in-class biologics targeting the IGFBP3/TMEM219 pathway
- Focus on preserving and re-establishing organ cell function
- Development of disease-modifying treatments for Type 1 Diabetes and Inflammatory Bowel Disease
- Libraries of monoclonal antibodies (mAbs) and fusion proteins